Back to discover
Drug

Radium-223

In clinical development
Emerging researchLate-stage development

Also known as 223-Ra, Ra-223, Radium 223, Radium Ra-223.

RxNorm1958200ChEMBLCHEMBL4297420UNII8BR2SOL3L1
3
Research papers
8
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Clinical trial2026-07-01Results expected Q1 2029 · ClinicalTrials.gov

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical trial2026-05-14Results expected Q2 2027 · ClinicalTrials.gov

A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer

Clinical trial2026-04-28Primary completion · ClinicalTrials.gov

Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer

Clinical trial2026-02-10Primary completion · ClinicalTrials.gov

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)

Clinical trial2026-02-06Results expected Q1 2028 · ClinicalTrials.gov

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Clinical trial2026-01-07Primary completion · ClinicalTrials.gov

A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)

Clinical trial2025-12-19Results posted · ClinicalTrials.gov

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

Clinical trial2025-09-30Completed · ClinicalTrials.gov

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.

Research2025-05-30Annals of oncology : official journal of the European Society for Medical Oncology

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.

Research2025-05-07Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Research2024-06-01Cancer immunology research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Radium-223
Aliases & brands
223-RaRa-223Radium 223Radium Ra-223
RxNorm CUI
1958200
ChEMBL ID
CHEMBL4297420
UNII
8BR2SOL3L1

Clinical trials

19 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
19
registered trials across all phases
LATEST COMPLETION 2025
8
Active studies
2
Recruiting
3
Late-stage (III+)
8
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 19
Early Phase 11Phase 14Phase 1 / 21Phase 210Phase 33

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

RecruitingPH IIIAstraZenecan=6702029

A Phase III Randomized Study Comparing the Combination of Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With Metastatic Castration-Sensitive Prostrate Cancer (mCSPC)

WithdrawnPH IIIGenesisCare USA2029

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, not recruitingPH IIIMemorial Sloan Kettering Cancer Centern=7322027

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

CompletedPH ITufts Medical Centern=432025

A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)

CompletedPH IISidney Kimmel Comprehensive Cancer Center at Johns Hopkinsn=642025

A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

CompletedPH IIDana-Farber Cancer Instituten=452025

Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

CompletedPH IIMemorial Sloan Kettering Cancer Centern=292022

A Phase II Clinical Trial of Radium-223 Activity in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status

CompletedPH IIMedSIRn=522021

Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

CompletedPH IDana-Farber Cancer Instituten=302019

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20242025
Major research themes7
Prostatic Neoplasms, Castration-Resistant3Radium3Bone Neoplasms2Antibodies, Monoclonal, Humanized1Antineoplastic Combined Chemotherapy Protocols1Phenylthiohydantoin1Radiosurgery1
Journals, researchers & institutions
Top journals
  • Annals of oncology : official journal of the European Society for Medical Oncology1
  • Cancer immunology research1
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
Leading researchers
  • Abramowitz MC1
  • Allaire KM1
  • Antonarakis ES1
  • Bazyar S1
  • Berlin A1
  • Bhatt RS1
  • Bompas E1
  • Bubley GJ1
Leading institutions
free-text, unnormalised
  • Beth-Israel Deaconess Medical Center1
  • Brady Urological Institute1
  • Broad Institute of Harvard and MIT1
  • Centre Hospitalier de l'Université de Montréal1
  • City of Hope Comprehensive Cancer Center1
  • Cliniques Universitaires Saint Luc1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Radium

Studied across 2 of the same disease areas as Radium-223 in the shared literature.

2 shared diseases2 shared papers
Enzalutamide

Studied across 2 of the same disease areas as Radium-223 in the shared literature.

2 shared diseases1 shared paper
Pembrolizumab

Studied across 2 of the same disease areas as Radium-223 in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials